A Phase 2 interventional study of Roflumilast Cream 0.05% and Roflumilast Cream 0.15% in Atopic Dermatitis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 20 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-02-13.
Sponsored by Arcutis Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing roflumilast in Dermatitis, Atopic — 4 open to participants now, 4 under way, 1 of them phase 3. Roflumilast · Dermatitis, Atopic.
Among the 13 studies testing roflumilast in Dermatitis, Atopic, this one is the 7th largest by enrollment, is one of 2 that started in 2019, is one of 4 in phase 2, and was the 2nd registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 13 studies testing roflumilast in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Integrative Skin Science and Research · Sites in United States
Ages 12+
Nora Mohamed Abdelrazik · Sites in Egypt
Ages 12+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 136 across the 13 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 13 have an industry lead sponsor. The 6 most frequent:
Arcutis Biotherapeutics, Inc. is the lead sponsor of 26 studies on the registry; 2 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 20 (83%) have results posted.
Arcutis Biotherapeutics, Inc. has 9 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
1 of the studies testing roflumilast in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07560618Integrative Skin Science and ResearchObtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream. | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing roflumilast in Dermatitis, Atopic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will assess the safety, pharmacokinetics (PK), and efficacy of different doses of roflumilast (ARQ-151) cream (0.05% and 0.15%) vs placebo applied once daily (QD) for 28 days by adolescents and adults with atopic dermatitis.
This is a parallel group, double blind, vehicle-controlled study in which roflumilast cream 0.05% or 0.15% or vehicle is applied QD x 28 days to adolescent and adult subjects with atopic dermatitis. A subset of subjects will have serial PK testing, which will include the first few adolescents and adults enrolled in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Known or suspected:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants apply roflumilast cream 0.05% QD for 28 days.
Drug: Roflumilast Cream 0.05%
Participants apply roflumilast cream 0.15% QD for 28 days.
Drug: Roflumilast Cream 0.15%
Participants apply vehicle cream QD for 28 days.
Drug: Vehicle Cream
Roflumilast 0.05% cream for topical application
Also known as: ARQ-151
Roflumilast 0.15% cream for topical application
Also known as: ARQ-151
Inactive vehicle cream matched to roflumilast cream for topical application.
Mean Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 4
The least squares (LS) mean (SD) change from baseline in EASI Total Score at Week 4 is reported. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.
Time frame: Baseline and Week 4
Percentage Change From Baseline in EASI Total Score
The LS mean (SD) percentage change from baseline in EASI Total Score at Weeks 1, 2, and 4 is reported. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.
Time frame: Baseline and Weeks 1, 2, and 4
Mean Change From Baseline in EASI Total Score at Weeks 1 and 2
The LS mean (SD) change from baseline in EASI Total Score at Weeks 1 and 2 is reported. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.
Time frame: Baseline and Weeks 1 and 2
Number of Participants Achieving a 50% Decrease From Baseline in EASI Score (EASI-50)
The number of participants with a decrease of at least 50% from the baseline EASI total score is presented. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease), with positive results indicating an increase from baseline in EASI total score (i.e., increased symptoms) and negative results indicating a decrease from baseline score (i.e., decreased symptoms). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.
Time frame: Baseline and Weeks 1, 2, and 4
Number of Participants Achieving a 75% Decrease From Baseline in EASI Score (EASI-75)
The number of participants with a decrease of at least 75% from the baseline EASI total score is presented. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease), with positive results indicating an increase from baseline in EASI total score (i.e., increased symptoms) and negative results indicating a decrease from baseline score (i.e., decreased symptoms). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.
Time frame: Baseline and Weeks 1, 2, and 4
Number of Participants Achieving a 90% Decrease From Baseline in EASI Score (EASI-90)
The number of participants with a decrease of at least 90% from the baseline EASI total score is presented. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease), with positive results indicating an increase from baseline in EASI total score (i.e., increased symptoms) and negative results indicating a decrease from baseline score (i.e., decreased symptoms). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI. In some instances, it was not possible to compare roflumilast to vehicle due to low number of cases.
Time frame: Baseline and Weeks 1, 2, and 4
Number of Participants Achieving a 100% Decrease From Baseline in EASI Score (EASI-100)
The number of participants with a decrease of 100% from the baseline EASI total score is presented. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease), with positive results indicating an increase from baseline in EASI total score (i.e., increased symptoms) and negative results indicating a decrease from baseline score (i.e., decreased symptoms). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI. In some instances, it was not possible to compare roflumilast to vehicle due to low number of cases.
Time frame: Baseline and Weeks 1, 2, and 4
Mean Change From Baseline in Body Surface Area (BSA) Involvement
The LS mean (SE) change from baseline in BSA involvement at Weeks 1, 2, and 4 is presented. The BSA affected by AD was determined by the subject's hand method, where the subject's hand (including fingers) surface area was assumed to equal 1% of BSA. Negative scores indicate improvement of symptoms, whereas positive scores indicate worsening.
Time frame: Baseline and Weeks 1, 2, and 4
Worse Itch Numerical Rating Score (WI-NRS) Score Change
The LS mean (SE) change from baseline in WI-NRS score is presented. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. Higher scores indicate greater symptom severity.
Time frame: Baseline and Weeks 1, 2, and 4
Number of Participants Achieving ≥4-Point Improvement in WI-NRS Pruritus Score
The number of participants achieving a ≥4-point improvement from Baseline in WI-NRS score is presented. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. Higher scores indicate greater symptom severity.
Time frame: Baseline and Weeks 1, 2, and 4
Adolescent (12 to 17 years of age) and adult (≥18 years of age) male and female participants with mild to moderate atopic dermatitis (AD) were enrolled at 3 study sites in Canada and 19 sites in the US.
| Milestone | Roflumilast Cream 0.05% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Started | 46 | 45 | 45 |
| Completed | 42 | 44 | 42 |
| Not completed | 4 | 1 | 3 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 | 1 |
| Withdrew: Worsening of ad | 0 | 0 | 1 |
The least squares (LS) mean (SD) change from baseline in EASI Total Score at Week 4 is reported. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.
| score on a scale | Roflumilast Cream 0.05% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Mean Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 4 | -6.03 ± 0.503 | -6.44 ± 0.492 | -4.84 ± 0.492 |
The LS mean (SD) percentage change from baseline in EASI Total Score at Weeks 1, 2, and 4 is reported. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.
| percent change | Roflumilast Cream 0.05% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 1 | -35.77 ± 4.297 | -34.67 ± 4.273 | -24.39 ± 4.279 |
| Week 2 | -54.30 ± 4.663 | -57.65 ± 4.567 | -48.48 ± 4.571 |
| Week 4 | -69.37 ± 4.643 | -72.32 ± 4.546 | -55.84 ± 4.551 |
The LS mean (SD) change from baseline in EASI Total Score at Weeks 1 and 2 is reported. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.
| score on a scale | Roflumilast Cream 0.05% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 1 | -3.11 ± 0.416 | -2.77 ± 0.57 | -2.19 ± 0.414 |
| Week 2 | -4.80 ± 0.479 | -5.02 ± 0.469 | -4.31 ± 0.470 |
The number of participants with a decrease of at least 50% from the baseline EASI total score is presented. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease), with positive results indicating an increase from baseline in EASI total score (i.e., increased symptoms) and negative results indicating a decrease from baseline score (i.e., decreased symptoms). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.
| Participants | Roflumilast Cream 0.05% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 1 | 14 | 11 | 10 |
| Week 2 | 27 | 23 | 22 |
| Week 4 | 32 | 33 | 25 |
The number of participants with a decrease of at least 75% from the baseline EASI total score is presented. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease), with positive results indicating an increase from baseline in EASI total score (i.e., increased symptoms) and negative results indicating a decrease from baseline score (i.e., decreased symptoms). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.
| Participants | Roflumilast Cream 0.05% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 1 | 4 | 6 | 1 |
| Week 2 | 8 | 14 | 11 |
| Week 4 | 26 | 23 | 14 |
The number of participants with a decrease of at least 90% from the baseline EASI total score is presented. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease), with positive results indicating an increase from baseline in EASI total score (i.e., increased symptoms) and negative results indicating a decrease from baseline score (i.e., decreased symptoms). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI. In some instances, it was not possible to compare roflumilast to vehicle due to low number of cases.
| Participants | Roflumilast Cream 0.05% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 1 | 0 | 1 | 0 |
| Week 2 | 1 | 6 | 4 |
| Week 4 | 8 | 12 | 8 |
The number of participants with a decrease of 100% from the baseline EASI total score is presented. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease), with positive results indicating an increase from baseline in EASI total score (i.e., increased symptoms) and negative results indicating a decrease from baseline score (i.e., decreased symptoms). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI. In some instances, it was not possible to compare roflumilast to vehicle due to low number of cases.
| Participants | Roflumilast Cream 0.05% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 1 | 0 | 0 | 0 |
| Week 2 | 1 | 2 | 0 |
| Week 4 | 1 | 5 | 1 |
The LS mean (SE) change from baseline in BSA involvement at Weeks 1, 2, and 4 is presented. The BSA affected by AD was determined by the subject's hand method, where the subject's hand (including fingers) surface area was assumed to equal 1% of BSA. Negative scores indicate improvement of symptoms, whereas positive scores indicate worsening.
| percentage of BSA affected | Roflumilast Cream 0.05% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 1 | -1.19 ± 0.407 | -1.67 ± 0.407 | -1.57 ± 0.405 |
| Week 2 | -2.69 ± 0.580 | -3.63 ± 0.570 | -3.29 ± 0.568 |
| Week 4 | -4.41 ± 0.658 | -5.10 ± 0.645 | -4.16 ± 0.644 |
The LS mean (SE) change from baseline in WI-NRS score is presented. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. Higher scores indicate greater symptom severity.
| score on a scale | Roflumilast Cream 0.05% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 1 | -2.21 ± 2.13 | -2.46 ± 0.361 | -1.7 ± 2.52 |
| Week 2 | -2.46 ± 0.415 | -2.76 ± 0.413 | -2.04 ± 0.408 |
| Week 4 | -3.34 ± 0.449 | -3.23 ± 0.444 | -2.73 ± 0.440 |
The number of participants achieving a ≥4-point improvement from Baseline in WI-NRS score is presented. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. Higher scores indicate greater symptom severity.
| Participants | Roflumilast Cream 0.05% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Week 1 | 11 | 15 | 9 |
| Week 2 | 10 | 15 | 16 |
| Week 4 | 21 | 17 | 18 |
Collected over Up to 32 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Roflumilast Cream 0.05% | 0/46 (0%) | 1/46 (2.2%) | 0/46 (0%) |
| Roflumilast Cream 0.15% | 0/45 (0%) | 0/45 (0%) | 0/45 (0%) |
| Vehicle Cream | 0/45 (0%) | 0/45 (0%) | 0/45 (0%) |
| Event | Roflumilast Cream 0.05% | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|---|
| Traumatic spinal cord compressionInjury, poisoning and procedural complications | 1/46 | 0/45 | 0/45 |
| Age, Continuous(years) | Roflumilast Cream 0.05% | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|---|
| Mean | 44.3 ± 16.98 | 38.0 ± 16.46 | 42.4 ± 17.64 | 41.6 ± 17.11 |
| Sex: Female, Male(Participants) | Roflumilast Cream 0.05% | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|---|
| Female | 31 | 33 | 29 | 93 |
| Male | 15 | 12 | 16 | 43 |
| Ethnicity (NIH/OMB)(Participants) | Roflumilast Cream 0.05% | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|---|
| Hispanic or Latino | 9 | 10 | 13 | 32 |
| Not Hispanic or Latino | 36 | 35 | 32 | 103 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Roflumilast Cream 0.05% | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 0 | 2 |
| Asian | 1 | 5 | 2 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 11 | 14 | 11 | 36 |
| White | 32 | 24 | 32 | 88 |
| More than one race | 0 | 2 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Baseline Eczema Area and Severity Index (EASI) Score(score on a scale) | Roflumilast Cream 0.05% | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|---|
| Mean | 8.44 ± 4.149 | 9.50 ± 4.097 | 9.20 ± 3.877 | 9.04 ± 4.039 |
| Baseline Body Surface Area (BSA) Score(percentage of body surface area) | Roflumilast Cream 0.05% | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|---|
| Mean | 8.4 ± 7.11 | 9.6 ± 5.99 | 10.5 ± 6.62 | 9.5 ± 6.60 |
| Baseline Worst Itch Numerical Rating Scale (WI-NRS) Score(score on a scale) | Roflumilast Cream 0.05% | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|---|
| Mean | 6.48 ± 1.986 | 6.60 ± 2.049 | 7.20 ± 2.106 | 6.76 ± 2.057 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2019 to primary completion in Nov 2019, 5 months.
Results were first posted in Feb 2023, 3 years 3 months after primary completion. A results delay was requested in Oct 2020.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 5 months is below that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roflumilast
Arcutis Biotherapeutics, Inc. →